|
Inhibitor Therapeutics Inc (HPPI) |
|
Inhibitor Therapeutics Inc
HPPI's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Inhibitor Therapeutics Inc 's sales fell
in I. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 0.34 %
Inhibitor Therapeutics Inc faced net loss in contrast to the net income a year ago in I. Quarter 2024
• More on HPPI's Growth
|
|
Inhibitor Therapeutics Inc realized a net loss in trailing twelve months.
Inhibitor Therapeutics Inc realized cash reduction of $ -0.02 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.15.
• More on HPPI's Valuation
|
|
|
|
|
Inhibitor Therapeutics Inc realized net loss in trailing twelve months.
Inhibitor Therapeutics Inc realized cash outflow of $ -0.02per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.15.
Inhibitor Therapeutics Inc Price to Book Ratio is at 3.22 lower than Industry Avg. of 79.01. and higher than S&P 500 Avg. of 0.01
• More on HPPI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com